TABLE 1.

Comparison between carriers of SCV and of normal colony types of P. aeruginosa and S. aureus

Clinical parametera	Patients infected with P. aeruginosa			Patients infected with S. aureus
	SCV	Normal colony type	P	SCV	Normal colony type	P
Total no.	9	53		8	32
Age (yr)	19 (12-23)	16 (1-37)	0.09	16.5 (3-36)	8 (1-40)	0.04
Age at colonization with P. aeruginosa (yr)	7.5 (0.6-11.5)	5.0 (0.2-28.1)	0.45
Age at colonization with S. aureus (yr)				4.1 (0.5-16)	4.2 (0.3-32.2)	0.35
Duration of colonization with P. aeruginosa (yr)	9.9 (5.5-18.4)	7.9 (0.1-23.4)	0.13	9.04 (0.3-12.9)	3.88 (0.25-16.2)b	0.08
Duration of colonization with S. aureus (yr)				14.9 (2.5-20.0)	2.4 (0.1-20.1)	0.007
Underweight (% of predicted weight) (<18 yr old)	14.0 (12.5-16.0)	2.7 (0-21.1)	0.02	6.8 (0-12.2)	1 (0-20.1)	0.4
Body-mass index (>18 yr old)	17.9 (13.6-20.0)	19.2 (16.6-21.9)	0.04	19.3 (16.6-21.9)	19.4 (18.2-21.1)	0.9
% of predicted FEV1	39.0 (21-90)	65.5 (24-125)	0.01	57.5 (21-109)	92.0 (32-122)	0.01
PaO2 (mm Hg)	64.0 (47.7-72.0)	71.5 (54.6-89.0)	0.004	66.8 (48.5-85.0)	74.0 (62-85)	0.07
Pretreatment with:
i.v. aminoglycosides
No. (%)	7 (77.7)	34 (64.1)	0.42	5 (62.5)	6 (18.1)	0.01
Duration (wks)	5 (0-11)	2 (0-16)	0.16	3 (0-16)	0 (0-4)	0.02
Topical aminoglycosides
No. (%)	7 (77.7)	26 (49.0)	0.11
Duration (wks)	31 (0-135)	0 (0-138)	0.33
Cotrimoxazole
No. (%)				7 (87.5)	11 (33.3)	0.01
Duration (wks)				42.5 (0-138)	0 (0-49)	0.001
Ciprofloxacin
No. (%)	8 (88.8)	41 (77.3)	0.43
Duration (wks)	27 (0-49)	6 (0-94)	0.07

^aDue to the small number of patients with SCV, summary measures are given as median (range). i.v., intravenous.

^bn = 24. Eight of 32 carriers of the normal phenotype of S. aureus were not coinfected with P. aeruginosa.